VIDEO INTERVIEW – Stable chronic angina: revascularization versus medical therapy

One of the major complications that can develop in patients with hypertension is coronary artery disease. The presence of stable coronary artery disease classifies a patient with hypertension as one at very high cardiovascular risk, irrespective of their blood pressure values (even if these are lower than 140 / 90 mmHg). Consequently, this pathological condition requires careful patient evaluation and appropriate treatment. Guidelines can help the clinician care for these patients, but it is important that signs and symptoms are carefully monitored and followed in individual patients to achieve the best outcome. An important issue is whether a patient with stable chronic angina should be revascularized or treated pharmacologically. In addition, for those for whom the choice is pharmacological treatment, what are the best options? This video interview will discuss the risks for patients with hypertension and stable coronary artery disease and the best therapeutic options to limit the negative cardiovascular consequences of the disease.

At the end of this activity, participants will be able to:

  1. Describe the pathogenetic mechanisms leading from hypertension to stable coronary artery disease
  2. Illustrate the cardiovascular risk linked to the presence of stable coronary artery disease
  3. Examine the evidence supporting revascularization of patients with stable coronary artery disease and discuss when the procedure is not appropriate
  4. Discuss the best therapeutic approach to improve outcomes in patients with hypertension and stable coronary artery disease

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.


Felix Mahfoud
Associate Professor
Department of Internal Medicine III
Cardiology, Angiology, Intensive Care Medicine
Saarland University Hospital
Homburg, Germany


Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.


Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Felix Mahfoud                       Declared no potential conflict of interest

All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This activity will be in English, with Arabic and Mandarin Chinese subtitles.

30 September 2021

Scientific Seminars International Foundation
Senior CME Manager: Flaminia Masprone
T +39 380 1504116 – F +39 06 4827169


This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.

Copyright 2021 Scientific Seminars International Foundation